Drugs / VT1021
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03364400 | Nov 2017 → Jan 2024 | cancer | Vigeo Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2023-07-13 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient vigeotx.com ↗
Now, after 3 years of dosing the tumor continues to be undetectable on regular MRI scans. |
| 2023-06-02 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session vigeotx.com ↗
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM). |
| 2023-05-25 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients vigeotx.com ↗
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM). |
| 2021-11-16 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting vigeotx.com ↗
Among 22 evaluable GBM subjects, 3 had complete response (CR), 1 had partial response (PR), and 7 had stable disease (SD). |
| 2021-11-09 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting vigeotx.com ↗
In the pancreatic cancer expansion cohort, VT1021, when administered as a single agent, was able to induce a reduction in tumor volume in 38% of subjects with measurable disease. |
| 2021-10-01 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting vigeotx.com ↗
The company will present data from the pancreatic cancer expansion cohort with single-agent VT1021 which demonstrated tumor reduction in multiple subjects with measurable disease. |
| 2021-09-21 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer vigeotx.com ↗
In the rGBM expansion cohort, single-agent VT1021 demonstrated complete tumor regression in multiple subjects and partial response in other subjects, with multiple subjects remaining on trial for well over 9 months. |
| 2020-11-09 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting vigeotx.com ↗
75% of Patients Who Achieved a Partial Response or Stable Disease Had High Expression of Both CD47 and CD36 |
| 2019-09-26 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress vigeotx.com ↗
Through the first eight dose levels tested, VT1021 has been shown to be safe and well tolerated, with no serious drug-related adverse events. |
| 2019-05-31 | Vigeo Therapeutics, Inc. | Results Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO vigeotx.com ↗
Through the first six dose levels tested, VT1021 has been shown to be safe and well tolerated with no serious drug related adverse events. |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03364400 ↗ |
| Action | Activate | “induces the expression of thrombospondin-1 (TSP-1)” PMID 38218979 ↗ Jan 2024 |
| Modality | Peptide | “VT1021 is a cyclic peptide” PMID 38218979 ↗ Jan 2024 |
| Route | Intravenous | “dosed twice weekly intravenously” PMID 38218979 ↗ Jan 2024 |